Myasthenia Gravis Treatment Market Will Experience Growth, Reaching US$4.1 Billion by the End of 2030, Predicts Persistence Market Research
23 janv. 2024 01h45 HE
|
Persistence Market Research
New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Myasthenia Gravis Treatment Market Poised for Steady Growth, driven by Innovation and Rising Awareness The global market for myasthenia gravis (MG)...
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
22 janv. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) --...
Contract Research Organization Market revenue to hit USD 108 Billion by 2035, says Research Nester
15 janv. 2024 06h00 HE
|
Research Nester
New York , Jan. 15, 2024 (GLOBE NEWSWIRE) -- The global contract research organization market size is slated to expand at 7% CAGR between 2023 and 2035. The market is poised to garner a revenue of...
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
03 janv. 2024 09h46 HE
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
21 déc. 2023 00h30 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
18 déc. 2023 06h30 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
15 déc. 2023 09h05 HE
|
Biogen Inc.
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...
U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
13 déc. 2023 14h03 HE
|
Spherix Global Insights
Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS)....
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
12 déc. 2023 07h00 HE
|
Athira Pharma, Inc.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
Global Medical Imaging Market Size to Reach USD 52.03 Billion in 2032 | Emergen Research
07 déc. 2023 09h10 HE
|
Emergen Research
Vancouver, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global medical imaging market, valued at USD 52.03 Billion in 2032, is set to experience substantial growth, with a projected revenue Compound Annual...